表紙
市場調查報告書

結核藥物的全球市場 2020-2030年:流行病學□主要國家□治療藥物□主要企業

Global Tuberculosis Treatment Drugs Market Report 2020-2030: Forecasts & Analysis of Epidemiology by Regions/Markets, plus Analysis of Leading Nations, by Therapies & Leading Companies

出版商 Visiongain Ltd 商品編碼 940603
出版日期 內容資訊 英文 174 Pages
商品交期: 最快1-2個工作天內
價格
結核藥物的全球市場 2020-2030年:流行病學□主要國家□治療藥物□主要企業 Global Tuberculosis Treatment Drugs Market Report 2020-2030: Forecasts & Analysis of Epidemiology by Regions/Markets, plus Analysis of Leading Nations, by Therapies & Leading Companies
出版日期: 2020年04月01日內容資訊: 英文 174 Pages
簡介

結核病(TB)是全球性的公共衛生問題,2019年估計有10億例結核病,近年來相對穩定。到2020年,結核病治療的市場規模估計為10.8億美元。全球市場在2019年到2020年間增加了5.8%CAGR。對抗結核藥物的需求增加,對多藥耐藥結核病例的數量增加,政府消除結核病的舉措與開發中新藥□疫苗的增加,促進了2020年到2030年間的節核藥物市場成長。更因為出資增加與結核病仍然蔓延嚴重的國家投入的研究設施與相關企業更加促進此市場。

本報告是調查全球的結核藥物市場並提供,按細分市場和區域進行的市場分析和預測、市場發展的影響因素、競爭環境與主要企業介紹等,有系統而完整的資訊情報。

第1章 概說

  • 全球結核藥物市場概要

第2章 結核病(TB)的背景

  • 疾病的定義
  • 結核的傳染
    • 決定結核感染可能性的因素
    • 與感染有關的結核病患者的特徵
    • 增加結核桿菌感染可能性的環境因素
  • 患者亞型
    • 潛伏性結核(結核感染)
    • 活動性結核(結核)
    • 潛伏性結核感染(LTBI)與活動性結核之間的區別
  • 結核的症狀
    • 根據症狀和體徵對結核進行詳細分類
    • 耐藥結核病(MDR和XDR)
    • 耐多藥結核病
    • 超級耐多藥結核病
  • 診斷
    • 潛伏性結核感染(LTBI)的診斷
    • 活動性結核(ATBI)的診斷
    • ATS、IDSA、與疾管處(CDC)的診斷守則
    • 診斷管道
  • 結核的治療
    • 抗結核藥
    • 治療守則
    • 結核疫苗

第3章 結核病流行病學預測

  • 2018年WHO發表的意見
  • 全球結核流行病學
  • 美國結核流行病學
  • 歐洲結核流行病學
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 其他地區
  • 結核病負擔沉重的前30個國家

第4章 開發中新藥分析

  • 可期待的藥物
    • 改用藥物/治療藥物
    • 目前的測試方案
    • 開發中疫苗

第5章 促進市場的因素與障礙

  • 市場成長因素分係
  • 抗藥性結核分枝桿菌的全球計劃□治療內容記錄
  • 影響市場成長負面因素
    • 高價的治療藥物
    • 新興國家的監管不足和認識不足
  • 結核藥物的全球市場的SWOT分析

第6章 結核藥物的全球市場預測:以地區分

  • 主要地區市場
    • 結核藥物的全球市場:地區分析
    • 結核藥物的全球市場:不同地區的預測
    • 各地區的市場份額改變預測
  • 北美的結核藥物市場
    • 北美的結核藥物市場預測
  • 歐洲的結核藥物市場
    • 歐洲結核藥物市場預測
  • 拉丁美洲的結核藥物市場
    • 拉丁美洲結核藥物市場預測
  • 中東□非洲的結核藥物市場
    • 中東□非洲的結核藥物市場預測
  • 亞太地區的結核藥物市場
    • 亞太地區的結核藥物市場預測

第7章 結核藥物的全球市場預測:以治療藥物區別

  • 第一線結核藥物的全球市場
  • 第二線結核藥物的全球市場
  • 結核藥物的全球市場預測:以治療藥物區別
    • Isoniazid市場預測
    • rifampicin市場預測
    • 其他藥物市場預測

第8章 主要企業

  • JOHNSON & JOHNSON
    • 公司概要
    • 治療藥物
    • 主要上市產品與相關的最新開發動向
    • R&D開發中新藥與未來展望
    • 收益預估
  • LUPIN LIMITED
  • MACLEODS PHARMACEUTICALS LIMITED
  • PFIZER
  • 大塚製藥

第9章 結論

  • 結核藥物的全球市場
    • 當前主要結核病藥物領域
    • 主要企業
    • 主要地區市場
  • 結核藥物的全球市場預測
  • 結核藥物的全球市場的未來

第10章 VISIONGAIN的相關報告

第11章 PHARMA LEADER SERIES:製藥製造承包商(CMO)前30

第12章 VISIONGAIN的報告銷售訂單表格

目錄
Product Code: PHA0733

Tuberculosis (TB) is a major public health concern worldwide, with an estimated 10.0 million cases of tuberculosis in 2019, a number that has been relatively stable in recent years. It is interesting to see how WHO, and global companies have taken steps to end tuberculosis worldwide. The growing number of prevalence cases of Multi-Drug Resistant TB and cases of new and relapsed TB among the population of developing and under developing countries have.

Not only the development from the treatment point of view, but also the new development diagnostic tests will play an important role in shifting the dynamics of the tuberculosis market. More than 23 companies have formed an alliance with institutions in developing markets to support clinical therapeutic developments.

The Tuberculosis Treatment Drugs Market is growing at the noteworthy CAGR of 5.8% with the estimated market size of $1,080 million in 2020. Globally market is registered to grow at the CAGR of 5.8% from 2019 to 2020. Growing needs of anti-tuberculosis drugs, increase in multi drug resistance TB cases, government initiatives towards TB elimination and the increase in the pipeline drugs as well as the vaccines will drive the growth of the TB market from 2020 to 2030. In addition, increase in funding will further boost up the institutes and the companies for research in the high TB burden countries.

The Tuberculosis Treatment Drugs Market Report explains the findings of the research of the Tuberculosis treatment market developments and growth factors which is driving the market. It notes key findings and makes recommendations for action for the companies who are actively participating and involved in the R&D of the tuberculosis therapies.

  • Understand the dynamics of TB market
  • Epidemiology Forecast and Analysis Globally and Regionally
  • Market Forecast & Analysis by Regions, By Nations, By Therapies & By Companies
  • Promising Therapies in the pipeline
  • Shift from generics to the effective TB therapies
  • WHO initiatives to end Global TB
  • Growing demand of effective therapies in developed/ developing countries
  • High TB Burden countries and funding appropriations
  • Effective Diagnostic Tests recently launched & under development

Leading Companies in the Tuberculosis Drugs Market:

  • Johnson & Johnson
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Pfizer
  • Otsuka Pharmaceuticals

Buy our report today Global Tuberculosis Treatment Drugs Market Report 2020-2030: Forecasts & Analysis of Epidemiology by Regions (United States, Europe, Germany, France, Italy, Spain, UK, Japan & Rest of the World), by Regional Markets (North America, Latin America, Middle East & Africa, Asia & Asia Pacific), Plus Analysis of Leading Nations, by Therapies & Leading Companies. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

TABLE OF CONTENTS

1 REPORT OVERVIEW

  • 1.1 GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET OVERVIEW
    • 1.1.1 Global Tuberculosis Treatment Drugs Market Overview
    • 1.1.2 Why You Should Read This Report
    • 1.1.3 How This Report Delivers
    • 1.1.4 Key Questions Answered by This Analytical Report
    • 1.1.5 Who is This Report For?
    • 1.1.6 Methodology
    • 1.1.7 Frequently Asked Questions (FAQ)
    • 1.1.8 Associated Visiongain Reports
    • 1.1.9 About Visiongain

2 TUBERCULOSIS (TB) DISEASE BACKGROUND

  • 2.1 DISEASE DEFINITION
  • 2.2 TRANSMISSION OF TB
    • 2.2.1 Factors that Determine the Probability of M. tuberculosis Transmission
    • 2.2.2 Characteristics of TB patient associated with Infection
    • 2.2.3 Environmental Factors that enhance the probability that M. tuberculosis will Be transmitted
  • 2.3 PATIENT SUBTYPES
    • 2.3.1 Latent TB (TB infection)
    • 2.3.2 Active TB (TB disease)
    • 2.3.3 Difference between Latent TB Infection (LTBI) and active TB Disease
  • 2.4 TUBERCULOSIS SYMPTOMS
    • 2.4.1 On the basis of Signs and Symptoms, TB can be further Classified into: -
    • 2.4.2 Drug-Resistant TB (MDR and XDR)
    • 2.4.3 Multidrug-Resistant TB
    • 2.4.4 Extensively Drug-Resistant TB
  • 2.5 DIAGNOSIS
    • 2.5.1 Diagnosis of Latent tuberculosis infection (LTBI)
    • 2.5.2 Diagnosis of Active tuberculosis infection (ATBI)
    • 2.5.3 Guidelines for Diagnosis from the ATS, IDSA, and Control of Disease Prevention & Control (CDC)
    • 2.5.4 Diagnostic Pipeline
  • 2.6 TREATMENTS FOR TUBERCULOSIS
    • 2.6.1 Anti-Tuberculosis Drugs
    • 2.6.2 Treatment Guidelines
    • 2.6.3 Tuberculosis Vaccine

3 TUBERCULOSIS EPIDEMIOLOGY FORECAST 2019-2020

  • 3.1 WORLD HEALTH ORGANIZATION ESTIMATES FOR 2018: -
  • 3.2 THE GLOBAL TUBERCULOSIS EPIDEMIOLOGY (2019-2030)
  • 3.3 THE UNITED STATES TUBERCULOSIS EPIDEMIOLOGY (2019-2030)
  • 3.4 THE EUROPE TUBERCULOSIS EPIDEMIOLOGY (2019-2030)
    • 3.4.1 Germany Tuberculosis Epidemiology (2019-2030)
    • 3.4.2 France Tuberculosis Epidemiology (2019-2030)
    • 3.4.3 Italy Tuberculosis Epidemiology (2019-2030)
    • 3.4.4 Spain Tuberculosis Epidemiology (2019-2030)
    • 3.4.5 The United Kingdom Tuberculosis Epidemiology (2019-2030)
  • 3.5 JAPAN TUBERCULOSIS EPIDEMIOLOGY (2019-2030)
  • 3.6 ROW TUBERCULOSIS EPIDEMIOLOGY (2019-2030)
  • 3.7 30 HIGH TB BURDEN COUNTRIES, 2020

4 PIPELINE DRUGS ANALYSIS, 2020

  • 4.1 PROMISING THERAPIES
    • 4.1.1 Repurposed Drugs/Therapeutics
    • 4.1.2 Current Regimen Trials
    • 4.1.3 Pipeline Vaccine

5 MARKET DRIVERS & BARRIERS

  • 5.1 MARKET DRIVERS ANALYSIS
  • 5.2 GLOBAL PLAN AGAINST DRUG-RESISTANT TB DRIVES DIAGNOSIS AND TREATMENT ENROLMENT
  • 5.3 MARKET RESTRAINTS ANALYSIS
    • 5.3.1 High Cost of Drugs
    • 5.3.2 Poor regulation and lack of awareness in developing countries
  • 5.4 SWOT ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET

6 GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST BY REGIONS 2019-2030

  • 6.1 LEADING REGIONAL MARKETS 2020-2030
    • 6.1.1 Geographical Breakdown of the Global Tuberculosis Drugs Market
    • 6.1.2 Global Tuberculosis Drugs Market: Regional Forecast 2020-2030
    • 6.1.3 How Will Regional Market Shares Change to 2030?
  • 6.2 NORTH AMERICA TUBERCULOSIS DRUGS MARKET 2020-2030
    • 6.2.1 North America Tuberculosis Drugs Market: Forecast 2020-2030
  • 6.3 EUROPE TUBERCULOSIS DRUGS MARKET 2020-2030
    • 6.3.1 Europe Tuberculosis Drugs Market Forecast 2020-2030
  • 6.4 LATIN AMERICA TUBERCULOSIS DRUGS MARKET 2020-2030
    • 6.4.1 Latin America Tuberculosis Drugs Market: Forecast 2020-2030
  • 6.5 MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET 2020-2030
    • 6.5.1 Middle East & Africa Tuberculosis Drugs Market: Forecast 2020-2030
  • 6.6 ASIA AND ASIA PACIFIC TUBERCULOSIS DRUGS MARKET 2020-2030
    • 6.6.1 Asia and Asia Pacific Tuberculosis Drugs Market: Forecast 2020-2030

7 GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST BY THERAPIES 2019-2030

  • 7.1 FIRST LINE TUBERCULOSIS TREATMENT DRUGS MARKET 2019-2030
  • 7.2 SECOND LINE TUBERCULOSIS TREATMENT DRUGS MARKET 2019-2030
  • 7.3 TUBERCULOSIS TREATMENT DRUGS MARKET BY THERAPIES 2019-2030
    • 7.3.1 Isoniazid Market Forecast 2020-2030
    • 7.3.2 Rifampin Market Forecast 2020-2030
    • 7.3.3 Other Drugs Market Forecast 2020-2030

8 LEADING COMPANIES IN THE TUBERCULOSIS DRUGS MARKET

  • 8.1 JOHNSON & JOHNSON
    • 8.1.1 Company Overview
    • 8.1.2 Johnson & Johnson 2019 Therapeutics
    • 8.1.3 Latest Developments Related to Key Marketed Products
    • 8.1.4 Johnson & Johnson, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
    • 8.1.5 Johnson & Johnson, Revenue Forecast, 2020-2025
  • 8.2 LUPIN LIMITED
    • 8.2.1 Company Overview
    • 8.2.2 Lupin 2019 Therapeutics
    • 8.2.3 Latest Developments Related to Key Marketed Products
    • 8.2.4 Lupin, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
    • 8.2.5 Lupin, Revenue Forecast, 2020-2025
  • 8.3 MACLEODS PHARMACEUTICALS LIMITED
    • 8.3.1 Company Overview
    • 8.3.2 Macleods Pharmaceuticals Limited 2019 Therapeutics
    • 8.3.3 Latest Developments Related to Key Marketed Products
    • 8.3.4 Macleods Pharmaceuticals Limited, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
    • 8.3.5 Macleods Pharmaceuticals Limited, Revenue Forecast, 2020-2025
  • 8.4 PFIZER
    • 8.4.1 Company Overview
    • 8.4.2 Pfizer 2019 Therapeutics
    • 8.4.3 Latest Developments Related to Key Marketed Products
    • 8.4.4 Pfizer, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
    • 8.4.5 Pfizer, Revenue Forecast, 2020-2025
  • 8.5 OTSUKA PHARMACEUTICALS
    • 8.5.1 Company Overview
    • 8.5.2 Otsuka Pharmaceuticals 2019 Therapeutics
    • 8.5.3 Latest Developments Related to Key Marketed Products
    • 8.5.4 Otsuka Pharmaceuticals, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
    • 8.5.5 Otsuka Pharmaceuticals, Revenue Forecast, 2020-2025

9 CONCLUSIONS

  • 9.1 GLOBAL TUBERCULOSIS DRUGS MARKET IN 2019, 2025 AND 2030
    • 9.1.1 Current Leading Tuberculosis Drugs Segments
    • 9.1.2 Leading Tuberculosis drugs Companies
    • 9.1.3 Leading Regional Markets
  • 9.2 GLOBAL TUBERCULOSIS DRUGS MARKET FORECAST 2020-2030
  • 9.3 THE FUTURE OF THE TUBERCULOSIS DRUGS MARKET?

10 ASSOCIATED VISIONGAIN REPORTS

11 PHARMA LEADER SERIES: TOP 30 PHARMACEUTICAL CONTRACT MANUFACTURING ORGANISATIONS (CMOS) 2020-2030

12 VISIONGAIN REPORT SALES ORDER FORM

  • 12.1 ABOUT VISIONGAIN
  • 12.2 VISIONGAIN REPORT EVALUATION FORM

LIST OF TABLES

  • TABLE 1.1 GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET OVERVIEW, 2020-2030
  • TABLE 2.1 KEY FACTS ABOUT TUBERCULOSIS
  • TABLE 2.2 FACTORS THAT DETERMINE THE PROBABILITY OF TRANSMISSION OF M. TUBERCULOSIS
  • TABLE 2.3 DIFFERENCE BETWEEN LATENT TB INFECTION (LTBI) AND TB DISEASE
  • TABLE 2.4 TESTING OF TB INFECTIONS
  • TABLE 2.5 OVERVIEW OF PROGRESS IN THE DEVELOPMENT OF TB DIAGNOSTICS, AUGUST 2019
  • TABLE 2.6 LATENT TB INFECTION TREATMENT REGIMENS
  • TABLE 2.7 REGIMENS FOR TREATING TB DISEASE
  • TABLE 3.1 GLOBAL TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.2 GLOBAL TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.3 GLOBAL TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.4 GERMANY TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.5 FRANCE TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.6 ITALY TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.7 SPAIN TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.8 THE UNITED KINDOM TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.9 JAPAN TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.10 ROW TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • TABLE 3.11 30 HIGH TB BURDEN COUNTRIES, 2018
  • TABLE 4.1: 2019 GLOBAL NEW DRUG TB PIPELINE
  • TABLE 4.2: 2019 REPURPOSED/EXISTING DRUG TB PIPELINE
  • TABLE 4.3: 2019 CLINICAL REGIMEN TRIALS
  • TABLE 5.1 SWOT ANALYSIS
  • TABLE 6.1 GLOBAL TUBERCULOSIS DRUG MARKET BY PRODUCT: REVENUE ($M) AND MARKET SHARE (%), 2019
  • TABLE 6.2 GLOBAL TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.3 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.4 GLOBAL TUBERCULOSIS DRUGS MARKET FORECAST BY REGION: REVENUES ($M, AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.5 NORTH AMERICA TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.6 TUBERCULOSIS DRUGS MARKET FORECAST BY COUNTRIES: REVENUES ($M, AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.7 UNITED STATES TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.8 CANADA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.9 EUROPE TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.10 EUROPE TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.11 GERMANY TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.12 FRANCE TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.13 ITALY TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.14 SPAIN TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.15 UNITED KINGDOM TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.16 LATIN AMERICA TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.17 TUBERCULOSIS DRUGS MARKET FORECAST BY COUNTRIES: REVENUES ($M, AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.18 BRAZIL TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.19 MEXICO TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.20 MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.21 TUBERCULOSIS DRUGS MARKET FORECAST BY COUNTRIES: REVENUES ($M, AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.22 SOUTH AFRICA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.23 NIGERIA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.24 ASIA & ASIA PACIFIC TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 6.25 TUBERCULOSIS DRUGS MARKET FORECAST BY COUNTRIES: REVENUES ($M, AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.26 INDIA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.27 CHINA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 6.28 CHINA TUBERCULOSIS DRUG MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 7.1 FIRST LINE TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019- 2030
  • TABLE 7.2 SECOND LINE TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 7.3 TUBERCULOSIS TREATMENT DRUGS MARKET BY THERAPIES: REVENUES ($M) AND MARKET SHARE(%), 2019 AND 2030
  • TABLE 7.4 TUBERCULOSIS TREATMENT ISONIAZID MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 7.5 TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • TABLE 7.6 TUBERCULOSIS TREATMENT OTHER DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019- 2030
  • TABLE 8.1 JOHNSON & JOHNSON: COMPANY OVERVIEW, 2019
  • TABLE 8.2 JOHNSON & JOHNSON: PRODUCTS PORTFOLIO, 2019
  • TABLE 8.3 JOHNSON & JOHNSON: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • TABLE 8.4 LUPIN: COMPANY OVERVIEW, 2019
  • TABLE 8.5 LUPIN: PRODUCTS PORTFOLIO, 2019
  • TABLE 8.6 LUPIN: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • TABLE 8.7 MACLEODS PHARMACEUTICALS LIMITED: COMPANY OVERVIEW, 2019
  • TABLE 8.8 MACLEODS PHARMACEUTICALS LIMITED: PRODUCTS PORTFOLIO, 2019
  • TABLE 8.9 MACLEODS PHARMACEUTICALS LIMITED: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • TABLE 8.10 PFIZER: COMPANY OVERVIEW, 2019
  • TABLE 8.11 PFIZER: PRODUCTS PORTFOLIO, 2019
  • TABLE 8.12 PFIZER: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • TABLE 8.13 OTSUKA PHARMACEUTICALS: COMPANY OVERVIEW, 2019
  • TABLE 8.14 OTSUKA PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2019
  • TABLE 8.15 OTSUKA PHARMACEUTICALS: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025

LIST OF FIGURES

  • FIGURE 2.1 SUMMARY OF RECOMMENDATIONS FOR LATENT TUBERCULOSIS INFECTION (LTBI) TESTING
  • TABLE 2.2 SUMMARY OF RECOMMENDATIONS FOR LTBI TESTING
  • FIGURE 3.1 GLOBAL TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.2 UNITED STATES TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.3 EUROPE TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.4 GERMANY TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.5 FRANCE TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.6 ITALY TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.7 SPAIN TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.8 THE UNITED KINDOM TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.9 JAPAN TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 3.10 ROW TUBERCULOSIS INCIDENCE CASES FORECAST, 2019-2030 (IN 000'S)
  • FIGURE 4.1 2019 GLOBAL NEW TB VACCINE PIPELINE
  • FIGURE 6.1 GLOBAL TUBERCULOSIS DRUG MARKET BY REGIONS: MARKET SHARE (%), 2019
  • FIGURE 6.2 GLOBAL TUBERCULOSIS DRUG MARKET SIZE, BY REGION: REVENUE($M), CAGR (%), 2019-2030
  • FIGURE 6.3 GLOBAL TUBERCULOSIS DRUG MARKET FORECAST: REVENUE ($M) AND AGR (%), 2019-2030
  • FIGURE 6.4 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: REVENUES ($M), 2019
  • FIGURE 6.5 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: REVENUES ($M), 2030
  • FIGURE 6.6 GLOBAL TUBERCULOSIS DRUGS MARKET BY COUNTRY/REGION: REVENUES ($M), 2019-2030
  • FIGURE 6.7 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: MARKET SHARES (%), 2019
  • FIGURE 6.8 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: MARKET SHARES (%), 2024
  • FIGURE 6.9 GLOBAL TUBERCULOSIS DRUGS MARKET BY REGION: MARKET SHARES (%), 2030
  • FIGURE 6.10 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2019
  • FIGURE 6.11 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2030
  • FIGURE 6.12 NORTH AMERICA TUBERCULOSIS DRUGS MARKET BY COUNTRY/REGION: REVENUES ($M), 2019-2030
  • FIGURE 6.13 U.S. TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.14 CANADA TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.15 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2019
  • FIGURE 6.16 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2030
  • FIGURE 6.17 EUROPE TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.18 GERMANY TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.19 FRANCE TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.20 ITALY TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.21 SPAIN TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.22 UNITED KINGDOM TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.23 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2019
  • FIGURE 6.24 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2030
  • FIGURE 6.25 LATIN AMERICA TUBERCULOSIS DRUGS MARKET BY COUNTRY/REGION: REVENUES ($M), 2019-2030
  • FIGURE 6.26 BRAZIL TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.27 MEXICO TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.28 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2019
  • FIGURE 6.29 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2030
  • FIGURE 6.30 MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET BY COUNTRY/REGION: REVENUES ($M), 2019-2030
  • FIGURE 6.31 SOUTH AFRICA TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.32 NIGERIA TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.33 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2019
  • FIGURE 6.34 TUBERCULOSIS DRUGS MARKET BY COUNTRIES: REVENUES ($M), 2030
  • FIGURE 6.35 ASIA AND ASIA PACIFIC TUBERCULOSIS DRUGS MARKET BY COUNTRY/REGION: REVENUES ($M), 2019-2030
  • FIGURE 6.36 INDIA TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.37 CHINA TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 6.38 JAPAN TUBERCULOSIS DRUGS MARKET FORECAST: REVENUES ($M) AND AGR(%), 2019-2030
  • FIGURE 7.1 FIRST LINE TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019- 2030
  • FIGURE 7.2 SECOND LINE TUBERCULOSIS TREATMENT DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • FIGURE 7.3 TUBERCULOSIS DRUGS MARKET BY THERAPIES: REVENUES ($M), 2019
  • FIGURE 7.4 TUBERCULOSIS DRUGS MARKET BY THERAPIES: REVENUES ($M), 2030
  • FIGURE 7.5 TUBERCULOSIS TREATMENT ISONIAZID MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • FIGURE 7.6 TUBERCULOSIS TREATMENT RIFAMPIN MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019-2030
  • FIGURE 7.7 TUBERCULOSIS TREATMENT OTHER DRUGS MARKET FORECAST: REVENUES ($M), AGR (%), AND CAGR (%), 2019- 2030
  • FIGURE 8.1 JOHNSON & JOHNSON: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • FIGURE 8.2 LUPIN: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • FIGURE 8.3 MACLEODS PHARMACEUTICALS LIMITED: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020- 2025
  • FIGURE 8.4 PFIZER: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • FIGURE 8.5 OTSUKA PHARMACEUTICALS: REVENUE FORECAST, REVENUES ($M), AGR (%), AND CAGR (%), 2020-2025
  • FIGURE 9.1 GLOBAL TUBERCULOSIS DRUGS MARKET REVENUE ($MILLION): 2019, 2025 AND 2030
  • FIGURE 9.2 LEADING REGIONAL MARKETS REVENUE ($MILLION): 2019, 2025, AND 2030